..

Global Journal of Technology and Optimization

ISSN: 2229-8711

Open Access

Jagat R Kanwar

Jagat R Kanwar

Jagat R Kanwar
Professor, Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research
Deakin University, Australia

Biography

Dr Jagat R Kanwar is the Professor in Nanomedicine and Head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (N-LIMBR) at School of Medicine (SoM), Molecular and Medical Research (MMR) Strategic Research Centre, Faculty of Health, Deakin University. He has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies. He has more than 120 publications in high impact factor and peer reviewed international journals, 17 book chapters and 2 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. He is an active member and delegate in various professional bodies including American Society of Nanomedicine, Australian Nanotechnology network, and a regular grant reviewer for national, international and corporate funding agencies.

Research Interest

Drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders.

arrow_upward arrow_upward